AUS
NZ
UK
CA
USA
IND
Highlights
Roche’s investigational antibody NXT007 progresses to phase III development
Positive early trial data shared at ISTH Congress for haemophilia A
Roche (LON:0QOK) operates under FTSE 100 and FTSE indices
Operating under the FTSE 100 and FTSE, F. Hoffmann-La Roche Ltd (LON:0QOK) is positioned within the healthcare segment, developing therapies across oncology, immunology, infectious diseases, and more. As a member of the broader pharmaceutical landscape, the company focuses on targeted innovation and novel drug development across therapeutic areas. The recent progress in its haemophilia programme signals continued involvement in rare disease research.
NXT007 Introduced as a Next-Generation Bispecific Antibody
NXT007 is Roche’s next-generation investigational bispecific antibody, designed to address the therapeutic needs of individuals with haemophilia A. Developed by Chugai, a subsidiary of Roche Group, this therapy is part of Roche’s pipeline to expand its haemophilia care offerings. The antibody is intended to normalise haemostasis and reduce treatment burden for individuals who do not have factor VIII inhibitors.
Phase I/II Findings Shared During Industry Conference
Early clinical data for NXT007 were presented during the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress. The trial, which included different dose groups, reported that the highest dose groups experienced no bleeds requiring treatment. No thromboembolic events were reported, and the safety profile was tolerable. These results support the drug’s continuation into advanced clinical trial phases.
Multiple Phase III Studies Planned for NXT007
A comprehensive development plan for NXT007 includes three phase III clinical studies scheduled to commence in 2026. One of these studies involves a direct comparison with Roche’s current treatment Hemlibra, which was previously introduced as the first prophylactic haemophilia A therapy with subcutaneous administration. The aim is to evaluate sustained bleed protection, reduced reliance on factor replacement, and improved convenience through flexible dosing.
Expansion of Haemophilia Portfolio by Roche
The focus of Roche’s haemophilia research programme is to widen treatment choices and improve patient quality of life. NXT007’s development is being pursued with the goal of minimising daily treatment concerns, increasing freedom from disease vigilance, and offering durable bleed protection. Roche’s previous experience with bispecific antibodies and existing products in this therapeutic class contributes to the scientific framework backing NXT007’s development.
Chugai’s Role Within Roche’s R&D Network
Chugai Pharmaceutical Co., Ltd., a core subsidiary of Roche, plays a key role in the design and engineering of NXT007. Known for its role in creating novel therapeutic antibodies, Chugai supports Roche’s broader efforts in the field of haemostasis. The strategic collaboration within Roche Group strengthens the development of innovative biologics targeted at unmet clinical needs.
Haemophilia Care Remains a Strategic Focus
Roche continues to direct clinical research efforts towards enhancing haemophilia care. The progression of NXT007 aligns with this approach, aiming to complement existing therapies and extend Roche’s therapeutic reach within the FTSE 100 healthcare segment. With plans for further data releases and large-scale trials, the company is maintaining momentum in developing next-generation therapies in the rare disease space.
